Cormorant Asset Management, LP Alx Oncology Holdings Inc Transaction History

Cormorant Asset Management, LP

$1.74 Billion
Q1 2024

A detailed history of Cormorant Asset Management, LP transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Cormorant Asset Management, LP holds 3,142,079 shares of ALXO stock, worth $18.9 Million. This represents 2.02% of its overall portfolio holdings.

Number of Shares

3,142,079

Previous 3,142,079 -0.0%

Holding current value

$18.9 Million

Previous $46.8 Million 25.12%

% of portfolio

2.02%

Previous 2.82%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$4.81 - $15.38 $12.2 Million - $38.9 Million	2,530,000 Added 413.35%	3,142,079 $46.8 Million
Q4 2022 Feb 14, 2023	SELL	$9.51 - $12.95 $951,000 - $1.3 Million	-100,000 Reduced 14.04%	612,079 $6.9 Million
Q1 2022 May 16, 2022	SELL	$13.65 - $22.06 $682,500 - $1.1 Million	-50,000 Reduced 6.56%	712,079 $12 Million
Q4 2021 Feb 14, 2022	SELL	$21.49 - $74.4 $5.37 Million - $18.6 Million	-250,000 Reduced 24.7%	762,079 $16.4 Million
Q3 2021 Nov 15, 2021	BUY	$52.51 - $80.91 $6.44 Million - $9.92 Million	122,625 Added 13.79%	1,012,079 $74.8 Million

Q2 2021 Aug 16, 2021	BUY	$52.2 - $75.23 $401,104 - $578,067	7,684 Added 0.87%	889,454 $48.6 Million
Q4 2020 Feb 16, 2021	SELL	$34.11 - $112.26 $3.07 Million - $10.1 Million	-90,000 Reduced 9.26%	881,770 $76 Million
Q3 2020 Nov 16, 2020	BUY	$29.36 - $47.1 $28.5 Million - $45.8 Million	971,770 New	971,770 $36 Million

Others Institutions Holding ALXO

# of Institutions

115

Shares Held

38.4M

Call Options Held

132K

Put Options Held

19.7K

View Full List

About ALX ONCOLOGY HOLDINGS INC

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $246M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

More about ALXO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.

Account

Cormorant Asset Management, LP Alx Oncology Holdings Inc Transaction History